Patent · US Active

Soluble IL-17RA/RC fusion proteins and related methods

US8084231B2 · kind B2 · utility

2Cited by
3References
28Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 30, 2010
Grant dateDec 27, 2011
Priority date—
Expiry dateJun 30, 2030

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/32
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.